Kestra Medical insider plans sale of 2,380 shares

Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44.

Rhea-AI Filing Summary

Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.

Key Figures

Planned shares to be sold: 2,380 shares Aggregate market value of planned sale: $56,551.44 Vesting date of performance share units: 07/17/2026 +4 more

7 metrics

Planned shares to be sold 2,380 shares Common stock to be sold through Merrill Lynch on August 3, 2026

Aggregate market value of planned sale $56,551.44 Estimated value of 2,380 shares of common stock

Vesting date of performance share units 07/17/2026 Date performance share unit awards vested into common stock

Shares sold on July 30, 2026 4,117 shares Common stock sold by Timothy Moran

Proceeds on July 30, 2026 $93,758.64 Value of 4,117 shares of common stock sold

Shares sold on July 31, 2026 8,759 shares Common stock sold by Timothy Moran

Proceeds on July 31, 2026 $198,000.29 Value of 8,759 shares of common stock sold

Key Terms

performance share unit awards, equity compensation plan, aggregate market value

3 terms

performance share unit awards financial

"Vesting of performance share unit awards"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

aggregate market value financial

"2380 | 56551.44 | 58602497 | 08/03/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is being reported for Kestra Medical Technologies (KMTS)?

A planned sale of 2,380 shares of Kestra Medical Technologies common stock is reported, to be executed through Merrill Lynch on August 3, 2026 on NASDAQ, with an aggregate market value of $56,551.44.

How were the 2,380 Kestra Medical Technologies (KMTS) shares obtained?

The 2,380 shares come from the vesting of performance share unit awards on July 17, 2026. These awards were originally granted under the issuer’s equity compensation plan, then converted into common stock upon vesting.

Which prior Kestra Medical Technologies (KMTS) stock sales are disclosed?

The disclosure lists Timothy Moran’s sales of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026, both involving Kestra Medical Technologies common stock.

Who is the broker for the planned Kestra Medical Technologies (KMTS) share sale?

The planned sale of 2,380 common shares will be handled by Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281, with the transaction expected to occur on NASDAQ on August 3, 2026.

What type of awards underlie the planned Kestra Medical Technologies (KMTS) share sale?

The planned sale relates to performance share unit awards that vested on July 17, 2026. These units were granted as part of the issuer equity compensation plan and converted into common stock before the reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:41 PM Accepted by SEC EDGAR 08/03/2026 - 04:40 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001753958
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Moran Timothy P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	2380	56551.44	58602497	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			2380	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Timothy Moran 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	4117	93758.64
Timothy Moran 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/31/2026	8759	198000.29

144: Remarks and Signature

Remarks
Date of Notice	08/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Timothy Moran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)